U.S. markets close in 13 minutes
  • S&P 500

    3,850.29
    -2.78 (-0.07%)
     
  • Dow 30

    31,071.75
    -104.26 (-0.33%)
     
  • Nasdaq

    13,563.09
    +32.17 (+0.24%)
     
  • Russell 2000

    2,156.16
    +14.74 (+0.69%)
     
  • Crude Oil

    52.07
    -1.06 (-2.00%)
     
  • Gold

    1,855.00
    -10.90 (-0.58%)
     
  • Silver

    25.55
    -0.31 (-1.20%)
     
  • EUR/USD

    1.2173
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • GBP/USD

    1.3682
    -0.0049 (-0.35%)
     
  • USD/JPY

    103.8060
    +0.3010 (+0.29%)
     
  • BTC-USD

    33,681.94
    +3,198.20 (+10.49%)
     
  • CMC Crypto 200

    665.93
    +55.94 (+9.17%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

P/E Ratio Insights for Biogen

Benzinga Insights
·2 min read

 

Right now, Biogen Inc. (NASDAQ: BIIB) share price is at $249.81, after a 0.17% drop. Over the past month, the stock increased by 2.32%, but over the past year, it actually fell by 17.16%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

The stock is currently higher from its 52 week low by 11.89%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with Biotechnology stocks, and capitalize on the lower share price observed over the year. 

The P/E ratio is used by long-term shareholders to assess the company’s market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings. 

View more earnings on BIIB

Depending on the particular phase of a business cycle, some industries will perform better than others. 

Biogen Inc. has a lower P/E than the aggregate P/E of 38.45 of the Biotechnology industry. Ideally, one might believe that the stock might perform worse than its peers, but it’s also probable that the stock is undervalued. 

 

Price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors can become unable to attain key insights from trailing earnings.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.